FDA advisory panel endorses Johnson & Johnson one-shot COVID vaccine for emergency use

Axios
·1 min read

A Food and Drug Administration advisory panel on Friday recommended the authorization of Johnson & Johnson’s one-shot coronavirus vaccine for emergency use.

Why it matters: The FDA is expected to make a final decision within days on the J&J vaccine, which was found to be 66% effective against moderate to severe COVID. An emergency use authorization would allow distribution to immediately begin, helping streamline and speed up the vaccine rollout across the U.S.

Get market news worthy of your time with Axios Markets. Subscribe for free.

  • White House coronavirus coordinator Jeff Zients said on Wednesday that J&J will have 3 million to 4 million ready for distribution next week.

  • The Moderna and Pfizer-BioNtech shots are the only other vaccines that have received FDA authorization. Unlike Moderna's shot, J&J's vaccine does not require ultra-cold storage, simplifying the logistics of distribution.

Go deeper: FDA analysis finds Johnson & Johnson COVID vaccine is safe and effective

More from Axios: Sign up to get the latest market trends with Axios Markets. Subscribe for free